Literature DB >> 16843631

Serum total cholesterol as a biomarker for Alzheimer's disease: mid-life or late-life determinations?

Francesco Panza, Cristiano Capurso, Alessia D'Introno, Anna M Colacicco, Federico Vasquez, Giuseppe Pistoia, Antonio Capurso, Vincenzo Solfrizzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16843631     DOI： 10.1016/j.exger.2006.06.005

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN： 0531-5565            Impact factor:   4.032


× No keyword cloud information.
  5 in total

1.  Determination of Glucose and Cholesterol Using a Novel Optimized Luminol- CuO Nanoparticles-H2O 2 Chemiluminescence Method by Box-Behnken Design.

Authors:  Mohammad Javad Chaichi; Mahjoobeh Ehsani
Journal:  J Fluoresc       Date:  2015-05-26       Impact factor: 2.217

Review 2.  Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease.

Authors:  Rupinder K Sodhi; Nirmal Singh; Amteshwar S Jaggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-24       Impact factor: 3.000

Review 3.  The vascular contribution to Alzheimer's disease.

Authors:  Robin Altman; John C Rutledge
Journal:  Clin Sci (Lond)       Date:  2010-08-05       Impact factor: 6.124

Review 4.  PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.

Authors:  Gary Landreth; Qingguang Jiang; Shweta Mandrekar; Michael Heneka
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

5.  Royal Jelly Reduces Cholesterol Levels, Ameliorates Aβ Pathology and Enhances Neuronal Metabolic Activities in a Rabbit Model of Alzheimer's Disease.

Authors:  Yongming Pan; Jianqin Xu; Cheng Chen; Fangming Chen; Ping Jin; Keyan Zhu; Chenyue W Hu; Mengmeng You; Minli Chen; Fuliang Hu
Journal:  Front Aging Neurosci       Date:  2018-03-05       Impact factor: 5.750
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.